Abstract: Disclosed are pharmaceutical and cosmetic compositions that include 5 Alpha Dihydrotestosterone (or alternatively, 5?-DHT, 5 Alpha-DHT, 5 Alpha DHT, 5a-DHT, DHT), and associated methods of use and treatment that can be used alone or in combination with other treatments to provide, improve, or promote general well-being and health, including mental health, in a subject. In particular the compositions, methods, and uses can provide, promote, support, and/or improve outcomes associated with gender reassignment, gender transitioning, and/or gender-affirming therapy in a subject who may be in need thereof.

Abstract: The present invention relates to deuterated derivatives of lanifibranor, in particular for use in therapy, specifically in the treatment of fibrotic diseases.

Abstract: The invention provides therapeutic methods, pharmaceutical compositions, and unit dose formulations for treating movement disorders, such as using a muscarinic acetylcholine receptor inhibitor in combination with a muscarinic acetylcholine receptor activator to treat dystonia. In some aspects, the invention provides a method of treating a movement disorder in a patient, where the method comprises administering to a patient in need thereof (i) a muscarinic acetylcholine receptor inhibitor in an amount effective to treat the movement disorder and (ii) a muscarinic acetylcholine receptor activator in an amount effective to reduce the frequency and/or magnitude of at least one side effect of the muscarinic acetylcholine receptor inhibitor, to thereby treat the movement disorder.

Abstract: Provided herein are small molecule compounds and methods inhibiting human sulfotransferase 1A3 (SULT1A3) using these small molecule compounds. Methods of manufacturing and treatment are also disclosed.

Abstract: The present invention relates to crystalline forms of a KRas G12C inhibitor and salt thereof. In particular, the present invention relates to crystalline forms of the KRas G12C inhibitor 2-[(2S)-4-[7-(8-chloro-1-naphthyl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile, pharmaceutical compositions comprising the crystalline forms, processes for preparing the crystalline forms and methods of use thereof.

Abstract: Provided herein is the use of a compound of Formula (I): or a pharmaceutically acceptable salt thereof, for treating a disease characterized by amyloid and amyloid-like aggregates, e.g., Alzheimer's disease.

Abstract: The present invention relates to crystalline forms of a KRas G12C inhibitor and salt thereof. In particular, the present invention relates to crystalline forms of the KRas G12C inhibitor 2-[(2S)-4-[7-(8-chloro-1-naphthyl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile, pharmaceutical compositions comprising the crystalline forms, processes for preparing the crystalline forms and methods of use thereof.

Abstract: The present application belongs to the technical field of proteolysis-targeting chimeras (PROTACs), and discloses a PROTAC molecule and a preparation method and use thereof. A ligand for a target protein in the PROTAC molecule of the present application is a pyridine carboxylic acid-1-oxide derivative. In cell and zebrafish experiments, the PROTAC molecule exhibits no toxic and side effects at a drug concentration allowing a desired effect. At a cellular level, an inhibition level of the PROTAC molecule for human tyrosinase (TYR) reaches less than or equal to 1 ?mol/L. The PROTAC molecule in the present application can significantly reduce the generation of melanin by degrading TYR, and has excellent solubility, safety, and efficacy and a low effective concentration.

Abstract: The present invention provides a PPAR? activator containing a novel PPAR? agonist (peroxisome proliferator-activated receptor ?) as an active ingredient, and an exercise tolerance-improving agent containing the same as an active ingredient. The present invention is a PPAR? activator containing a guanidine derivative or a biguanidine derivative as an active ingredient, wherein the PPAR? activator activates transcriptional activity of PPAR?, and the guanidine derivative and the biguanidine derivative are capable of fitting within a PPAR? ligand binding pocket in a state where a guanidino group or a biguanidino group forms a hydrogen bond with amino acid residues corresponding to each of the 413th histidine, 287th histidine, 253rd threonine and the 437th tyrosine of human PPAR?, among amino acid residues constituting an interior surface of the ligand binding pocket; and is an exercise tolerance-improving agent containing the PPAR? activator as an active ingredient.

Abstract: A compound represented by formula (I) or a pharmaceutically acceptable salt, a stereoisomer, a tautomer, a polymorph, a solvate, an N-oxide, an isotope labeled compound, a metabolite or a prodrug thereof, a pharmaceutical composition and a pill container comprising same, a preparation method therefor, and the use thereof in the preparation of drugs for preventing or treating STING-mediated related diseases.

Abstract: A method for preparing a novel crystal form F of trelagliptin includes: adding a mediating protein into the trelagliptin to obtain a mixture, and introducing a mechanochemical action on the mixture for transformation of a crystal form of the trelagliptin to obtain the novel crystal form F of trelagliptin. The preparation method does not require any organic solvent and thus will not lead to an organic solvent residue to affect the safety of medication. In addition, the preparation method is less time-consuming than a solvent crystallization method, is easy to allow green industrial production, and has characteristics such as simplicity, high efficiency, safety, and environmental friendliness.

Abstract: This invention provides compounds of formula I: wherein a, b, c, d, m, n, p, s, t, W, Ar1, R1, R2, R3, R4, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

Abstract: The present invention relates to a compound selected from the group consisting of nolatrexed, triamterene, sultopride and hydrastinine or a pharmaceutically acceptable salt thereof, preferably triamterene, nolatrexed or a pharmaceutically acceptable salt thereof, and to combination of said compounds with other active ingredients, for use in the treatment and/or prevention of phenylketonuria, to the use of said compound or its combinations in the manufacture of a medicament for the treatment or prevention of said diseases and to a method of treating and/or preventing by administration of said compound or its combinations.

Abstract: The invention relates to a chemical synthesis method, the said method comprising “Spray Flash Evaporation”, also commonly referred to by the corresponding initialism SFE, which comprises the chemical reaction of at least one first compound with at least one second compound, under conditions in which the first compound and the second compound react to form at least one third compound. The invention also relates to a device for implementing this method and the compounds obtained by this method.

Abstract: The present invention is directed to cyclobutyl pyrazolopyrimidine compounds which may be useful as therapeutic agents for the treatment of disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating cardiovascular and cerebrovascular diseases, such as hypertension, chronic kidney disease and heart failure, and neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Abstract: The present disclosure relates to a pharmaceutical composition for prevention or treatment of circadian rhythm-related disorders, including an oxyiminomethylbenzene derivative or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed herein, inter alia, are compounds and methods of use thereof for the modulation of certain chemokine receptor activity.

Abstract: A method of use of Glyceryl Tris (Beta-hydroxybutyrate) in the minimization, reduction, or prevention of neuronal deficit and/or neuronal cell death with respect to follow-on neuronal transient ischemic attacks (NTIAs) in subjects who have had (or in subjects exhibiting symptomology of having had) at least one prior NTIA.

Abstract: The invention provides a series of GMPS enzyme inhibitors. The invention includes potent GMPS inhibitors that specifically and covalently bind to GMPS, exhibit broad anti-cancer activity, block the infection efficiency of viruses, and have the potentials to suppress undesired immune responses. These novel inhibitors of GMPS, and their derivatives, have tremendous potentials to be used as therapeutic agents for the treatment of cancers, viral infection and immune disorders.

Abstract: Provided herein are novel compounds, e.g., those of Formula (I), as GCN2 inhibitors. Also provided are pharmaceutical compositions including one or more of the novel compounds, and pharmaceutical uses thereof. Compounds provided herein can typically inhibit an activity of a GCN2 and thus can be used for treating or preventing diseases related thereto.